Clinical Trials
13 trialsNCT06246916 2026-05-06
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06413680 2026-04-28
BrILliance
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT06585410 2026-04-22
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT03017820 2026-04-13
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT05929664 2026-03-24
Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
Thomas Jefferson University
Phase 2 Recruiting
NCT06981325 2026-03-11
CEMI-first
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT06171750 2026-03-06
ANCHOR
Ankyra Therapeutics, Inc
Phase 1 Recruiting
NCT06022029 2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1 Recruiting
NCT06121180 2025-12-04
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07223411 2025-11-26
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
University of Pittsburgh
Recruiting
NCT07064330 2025-09-10
NGF-GRACE
Instituto de Investigación Biomédica de Salamanca
Recruiting
NCT04291105 2025-03-26
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Vyriad, Inc.
Phase 2 Recruiting
NCT06090266 2025-01-07
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Phase 1/2 Recruiting